Torsades de pointes induced by garenoxacin in association with pacing failure in an elderly woman with VDD pacemaker

Wang, 2007, Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers, Clin Ther, 29, 1098, 10.1016/j.clinthera.2007.06.015 Anderson, 2001, Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics, J Pharmacol Exp Ther, 296, 806 Milberg, 2007, Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes, J Cardiovasc Electrophysiol, 18, 647, 10.1111/j.1540-8167.2007.00793.x Takenaka, 2003, Exercise stress test amplifies genotype–phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome, Circulation, 107, 838, 10.1161/01.CIR.0000048142.85076.A2 Miyamoto, 2010, Torsades de pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice, Clin Exp Nephrol, 14, 164, 10.1007/s10157-009-0244-9 Katritsis, 2003, Quinolones: cardioprotective or cardiotoxic, Pacing Clin Electrophysiol, 26, 2317, 10.1111/j.1540-8159.2003.00367.x